Stocks and Investing Stocks and Investing
Mon, January 7, 2019
Fri, January 4, 2019
Thu, January 3, 2019
Wed, January 2, 2019
Mon, December 31, 2018
Fri, December 28, 2018
Thu, December 27, 2018
Wed, December 26, 2018
Fri, December 21, 2018
Thu, December 20, 2018
Wed, December 19, 2018
Tue, December 18, 2018
Mon, December 17, 2018
Fri, December 14, 2018

David Risinger Downgraded (AMRX) to Hold and Decreased Target to $18 on, Dec 14th, 2018


Published on 2024-10-26 11:16:57 - WOPRAI, David Risinger
  Print publication without navigation


David Risinger of Morgan Stanley, Downgraded "Amneal Pharmaceuticals, Inc." (AMRX) to Hold and Decreased Target from $24 to $18 on, Dec 14th, 2018.

David has made no other calls on AMRX in the last 4 months.



There are 2 other peers that have a rating on AMRX. Out of the 2 peers that are also analyzing AMRX, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Dewey Steadman of "Canaccord Genuity" Maintained at Hold with Increased Target to $21 on, Tuesday, August 14th, 2018


This is the rating of the analyst that currently disagrees with David


  • David Buck of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $28 on, Wednesday, August 22nd, 2018